Reaching Consensus on the Adoption of Oncology Biosimilars

Learn from expert faculty what key clinical considerations inform the use of biosimilars in oncology practice with this series of ClinicalThought&trade commentaries!

Share

Program Content

Activities

Biosimilar Integration
Addressing Barriers to Biosimilar Integration in Cancer Care
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2018

Expires: December 17, 2019

Available Biosimilars
Biosimilar Updates for Supportive and Therapeutic Cancer Care
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 18, 2019

Expires: January 17, 2020

Faculty

cover img faculity

Jeffrey Crawford, MD

George Barth Geller Professor for Research in Cancer

Duke University Medical Center

Co-director of the Solid Tumor Therapeutics Program

Duke Cancer Institute

Durham, North Carolina

cover img faculity

Gary Lyman, MD, MPH, FASCO, FRCP (Edin)

Co-Director, Hutchinson Institute for Cancer Outcomes Research (HICOR)
Public Health Sciences and Clinical Research Divisions
Fred Hutchinson Cancer Research Center
Professor of Medicine/Medical Oncology
University of Washington School of Medicine
Seattle, Washington

Provided by

ProCE Banner

Supporters

This activity is supported by an educational funding donation provided by

Amgen, Inc.